What You Should Know:

你应该知道的：

–

–

PGxAI

PGxAI

, a pioneering leader in the field of

，该领域的先锋领袖

AI-driven

人工智能驱动的

pharmacogenetics, today announced the launch of Deneb, its latest cutting-edge model poised to transform the landscape of drug development.

药理基因组学，今天宣布推出其最新的尖端模型Deneb，有望彻底改变药物开发的格局。

– Deneb is specifically designed to streamline this complex process by seamlessly integrating molecular structures, physicochemical properties, and comprehensive genetic profiles.

– Deneb 专为简化这一复杂过程而设计，能够无缝整合分子结构、物理化学性质和全面的遗传特征。

Drug Development for Biopharma

生物制药的药物开发

Tailored to meet the critical needs of biopharmaceutical companies and contract research organizations (CROs), Deneb delivers near real-time pharmacogenetic (PGx) recommendations. This capability promises to significantly reduce both the time and the substantial costs associated with clinical trials, while simultaneously increasing the probability of successful market entry for novel therapeutics..

专为满足生物制药公司和合同研究组织（CRO）的关键需求而设计，Deneb 提供近乎实时的药物基因组学（PGx）建议。该功能有望显著减少与临床试验相关的时间和高昂成本，同时提高新型治疗药物成功进入市场的概率。

By automating the traditionally labor-intensive process of PGx guideline creation, Deneb empowers researchers to precisely identify optimal patient cohorts for clinical trials. Furthermore, the model facilitates the refinement of drug dosing strategies and aids in the early anticipation of potential adverse drug reactions.

通过自动化传统上劳动密集型的PGx指南创建过程，Deneb使研究人员能够精确识别临床试验的最佳患者群体。此外，该模型有助于优化药物剂量策略，并帮助早期预测潜在的药物不良反应。

The ultimate outcome is a more targeted and data-driven approach to drug development, which effectively mitigates the risk of trial failures and accelerates the journey of safer, more effective therapies to the patients who need them..

最终结果是一种更具针对性和数据驱动的药物开发方法，这种方法有效降低了试验失败的风险，并加速了更安全、更有效的疗法走向需要它们的患者。

The development of Deneb is underpinned by PGxAI’s robust strategic partnerships with leading technology providers, including NVIDIA, InterSystems, Google, and Microsoft. These collaborations ensure seamless compatibility with existing research and development workflows within pharmaceutical organizations and CROs.

Deneb 的开发得益于 PGxAI 与包括 NVIDIA、InterSystems、Google 和 Microsoft 在内的领先技术供应商的强有力战略合作伙伴关系。这些合作确保了与制药组织和合同研究组织 (CRO) 现有的研发工作流程无缝兼容。

By intelligently integrating data from a multitude of diverse sources, Deneb firmly positions PGxAI as a crucial ally for pharmaceutical innovators who are driven to shorten development timelines, minimize adverse events, and deliver groundbreaking therapies to patients across the globe..

通过智能整合来自众多不同来源的数据，Deneb牢固地将PGxAI定位为制药创新者的得力盟友，助力他们缩短开发时间、减少不良事件，并为全球患者提供突破性的治疗方法。

“Clinical trial setbacks often stem from the wide variance in individual responses to drugs,” said Dr. Mike Zack, PGxAI co-founder and CEO. “Deneb tackles this challenge by leveraging AI and multi-omics data to rapidly predict how different patient groups will respond to a candidate drug — even before trials begin.

“临床试验的挫折往往源于个体对药物反应的广泛差异，”PGxAI联合创始人兼首席执行官迈克·扎克博士说道。“Deneb通过利用人工智能和多组学数据来迅速预测不同患者群体对候选药物的反应，甚至在试验开始之前就能做到这一点，从而应对这一挑战。”

This not only reduces costly trial failures but also expedites regulatory approvals.”.

这不仅减少了昂贵的试验失败，还加快了监管审批。